J B Chemicals & Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mm2gajmvh7slztdbw6vuus9k.pdf

Key Takeaways


The Post-Acquisition Reset

Aman Mehta: "I think the positive surprises definitely would be that the brands in the India business in particular continue to give us confidence that, you know, these are such widely established and recognized brands and familiarity is so high that in a merged entity it would certainly be possible to accelerate the growth further."

India Business: Trade Generics Exit Resets the Base


International & CDMO: Two Drags, Two Recoveries

Sanjay Gupta: "So essentially, they bring to you new products or new ideation and you have to develop and manufacture these products and supply to them. So JB has some delays in execution of these contracts which are on hand. So our job is to accelerate the delivery of these new products so that they can come into revenue quicker rather than later."

Synergies: Revenue and Procurement Starting to Flow


Margins: Gross Margin Up, Full-Year Guidance Deferred


Guidance & Commitments

CommitmentSpecificsTimeline
India branded business growthAccelerate by a few percentage points from current trajectory; return to double-digit growthCouple of quarters
International business recoveryReturn to single-digit growthPotentially Q1, more likely Q2
West Asia normalizationContainer constraints ease, business on trackQ2 onwards
Merger effectivenessHearing in second week of June; merger effectiveOne to two months max
CDMO momentumPositive momentum; flat is not normalOn a 12-month basis
Revenue synergiesBegin to materializeNext couple of quarters
Procurement synergiesStrong positive impact already from April; full impact may be muted by geopolitics in current yearFrom April
Distribution optimization margin impactVisibility in margin improvementFrom April

Key Metrics

MetricQ4 FY26
Revenue₹904 cr, de-growth of 5% YoY
Gross margin~70%, up from 66% in Q4 FY25
Adjusted EBITDA₹241 cr, flat YoY after adjusting for one-offs
Adjusted EBITDA margin~27%, up ~2 ppt from 25% in Q4 FY25
Reported net profit₹101 cr
Adjusted net profit₹150 cr, after adjusting for one-offs of ₹40 cr including non-cash ESOP charges
India business revenue₹526 cr, 2% YoY growth
India branded business growth8% YoY
International formulations revenue₹259 cr, de-growth of 9% YoY
CDMO business revenueDeclined 22% YoY due to high base
Net cash~₹1,200 cr as of FY26
India field force~2,500 MRs
Final dividend₹9.3 per equity share of ₹1 each for FY26